Miriam Merad, MD, PhD, presents an argument that moving to a immune-genomics classification of cancer will allow treatments to become more holistic and also lead to more effective, novel combinations of therapies. Dr. Merad discusses the new diagnostic tools that map the heterogeneous diversity of cancerous cells, which may, in the near future, facilitate the development of a data set of characteristics that can guide targeted therapies.